Google
EVGN 株価分析 — Evogene (Healthcare >> Biotechnology)
EVGN に関するよくある質問
EVGNのPER（株価収益率）は？
Evogene（EVGN）は現在PER 1.67倍で取引されています。
EVGNのROE（自己資本利益率）は？
EvogeneのROEは462.36%です。
EVGNの配当利回りは？
Evogeneの配当利回りは0.00%です。
EVGNの品質スコア（Quality Score）は？
当社のAIはEVGNの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EVGNは今が買い時ですか？
当社AIのタイミングスコアは100点中51点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EVGNはどのセクターに属しますか？
EvogeneはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
EVGN AI Analysis Summary
Our AI summary for EVGN: Evogene (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1.67, ROE of 462.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.65
Price
0.11
(21.27%)
Day Change
|
|
|---|
EVGN, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 72 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.65 |
| PBV / Sector |
0.81 / 44,022.72
GREAT
|
| Earning Per Share | -1.18 |
| PE / Sector |
1.67 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
-0.04 / 1.24
|
| Average 1M Daily Value |
1.02 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:09 |
| Symbol | EVGN |
| Name | EVOGENE |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 12.10 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6.49 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 13 Gad Feinstein Street, Rehovot, Israel, 7638517
Phone: 972 8 931 1900
Website: https://www.evogene.com
Employees: 52
Sector: Healthcare >> Biotechnology
Description: Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
